Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Pulmo BioTech Inc. Announces that Its Pulmonary Vascular Diagnostic Product Candidate PulmoBind Shows Early Indications of Being Able to Diagnose a Wide Range of Medical Conditions.

Pulmo BioTech Inc. has announced that early experimental results have indicated that its PulmoBind product candidate can be potentially used for the early detection and follow-up of many conditions that affect the physical and/or biological integrity of the Pulmonary Circulation. These early results, if confirmed by further experiments, would broaden the range of conditions that PulmoBind is able to diagnose.

"We are very pleased with these early results. To date, we have mainly concentrated on the use of PulmoBind as a diagnostic agent for Pulmonary Hypertension (PH) and Pulmonary Embolism (PE). While our work in these areas continues, early experimental results have indicated that PulmoBind could be used to diagnose a wide range of Pulmonary Vascular diseases associated with lung disorders, heart disease and connective tissue disease. For example, lung disorders associated with HIV, Cirrhosis and Shistosomiasis are all conditions that we believe could potentially be diagnosed using PulmoBind. If our experimental results can be confirmed, then PulmoBind has great potential as a front-line test to either confirm or exclude disorders of the Pulmonary Circulation in patients who present with "shortness of breath". PulmoBind could also help in predicting outcomes in these patients and guiding their therapy." - Garry McCann, CEO Pulmo BioTech Inc.

Source: Pulmo BioTech Inc.

You can discuss about Pulmo BioTech Inc. and its services in the Pulmo Bio Tech Company User Group.